The technology has not been officially recognized in the country and there are no patented devices. The country also did not pass the audit, the maturity of this technology does not have sufficient basis. In addition, many third-party testing organizations are operating privately, the market order is chaotic, the country needs to be rectified. And the cost of the test is more expensive, and the results can be basically understood from the Down's test, this way of inducing people to consume most of the way to meet the commercial interests.
Everyone knows that noninvasive is a new technology in the United States. But the U.S. health care does not apply this technology to clinical diagnosis, since the countries that invented this method have not been audited, the Chinese use obviously become for the Americans to do experiments, and even in the future to become a basis for this technology through the audit or not. The Chinese use of this method is obviously an experiment for the Americans, and even a basis for the future of this technology to pass or fail.
For the vast majority of pregnant women, the cost of the test is unaffordable, generally costing several thousand dollars. And more than 99 percent of the test results are basically normal.
The joint notice of the two ministries pointed out that gene sequencing-related products and technologies, including prenatal genetic testing, belong to the scope of contemporary cutting-edge technological research, involving ethics, privacy and protection of human genetic resources, biosafety, as well as medical institutions to carry out genetic diagnostic services, technology management, price, quality supervision and other issues.